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Proliferating smooth muscle cells can cause hemodialysis vascular access 
stenosis. Applying antiproliferative drugs like imatinib mesylate that inhibit growth 
factors using a delivery system that keeps these agents at the site of stenosis could inhibit 
these proliferating cells. The aim of the study was to understand the release kinetics of 
imatinib from an injectable gel and the effect of imatinib on inhibiting proliferation of 
vascular smooth muscle cells.  
 Imatinib mesylate was obtained from capsules or tablets and mixed with ReGel™. 
The release profile of imatinib from ReGel™ was studied in a release medium under both 
sink and nonsink conditions. Freebase of imatinib was also extracted and characterized 
by RP-HPLC and its release profile was studied under sink and nonsink conditions. The 
free base of imatinib was incubated with porcine smooth muscle cells to study the effect 
of the drug on its proliferative properties using the BrdU assay. 
 The results show that the release rates of imatinib mesylate or free base from 
ReGel™ were similar in sink and nonsink conditions. Imatinib salt or its free base 
released from the ReGel™ within 2-4 days. The concentrations required to inhibit 50% 
porcine vascular smooth muscle cells with free base was between 0.5-5 µM. 
 Imatinib release from ReGel™ is quick so its use for the prevention of 
hemodialysis vascular access stenosis would be limited. The quick release could interfere 
with the healing process after initial graft implantation and it would require frequent 
 
 readministrations. Imatinib release from ReGel™ therefore, needs to be prolonged by 
changing the delivery system to make this approach feasible before further evaluation for 
this application.        
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CHAPTER 1  
 INTRODUCTION 
1.1 Hemodialysis and vascular access 
Hemodialysis is a common procedure performed in patients with advanced and 
permanent renal failure. When kidneys fail to perform the function of removing harmful 
wastes from the blood it leads to increases in blood pressure and decreases in the 
production of red blood cells in the body (1). Hemodialysis is performed with a machine 
known as dialyzer that replaces the function of the kidneys in patients with renal failure 
(Figure 1-1).   
  Access to the patient’s blood by the dialyzer occurs through a vascular access 
catheter or graft that is placed in the patient’s forearm. Vascular access provides an 
anatomical location from which the blood is removed and replaced after it has been 
filtered through the dialyzer and it is usually surgically prepared weeks or months before 
dialysis is started in patients (Figure 1-1) (1). However, vascular access dysfunction in 
hemodialysis patients costs approximately $1 billion per annum in United States (2-4).  
Three main kinds of vascular access configuration for hemodialysis are used among 
patients(1): native arteriovenous fistulae (5), synthetic grafts commonly made of PTFE 
(polytetrafluoroethylene) (5) and dual-lumen cuffed catheters (6). Among these three 
access systems, synthetic PTFE grafts are most commonly used in United States (2, 7).

































Figure 1-1: The process of hemodialysis and dialyzer 
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1.2 Mechanism of development of intimal hyperplasia  
To understand the mechanism of development of intimal hyperplasia it is 
necessary to review the anatomy of the arterial wall. The arterial wall consists of three 
layers: intima, media and adventitia. The intima is nearest to the lumen (Figure 1-2). It 
contains type IV collagen, laminin and heparin sulphate proteoglycans. As shown in the 
Figure 1-2 the media is between the intima and the adventitia and contains vascular 
smooth muscle cells and type I and III collagen, fibronectin and chondroitin sulphate 
proteoglycans densely packed into an interstitial matrix. The outermost layer is adventitia 
and consists of fibroblasts in a loose connective tissue. Intimal hyperplasia results from 
an increase in the number of cells in the intima accompanied by increase in the 
extracellular matrix (8). The main reasons for formation of hyperplasia are hypothesized 
to be due to graft compliance mismatch, vessel stretch, surgical trauma and accumulation 
of various biochemical factors released from fibrin and platelets in the vessel lumen (9, 
10). The major reasons for inducing hyperplasia are injury, inflammation and stress (11).  
Injury stimulates smooth muscle cell (SMC) proliferation by causing endothelial 
disruption that leads to release of intracellular mitogens. The vascular smooth muscle 
cells then undergo transformation from a quiescent to a proliferative phenotype (12). This 
proliferation leads to production of extracellular matrix. It has also been hypothesized 
that damage in the endothelial layer leads to platelet adhesion due to exposure of 
collagen. Platelet derived growth factor (PDGF) is released following aggregation of 
platelets (13). It has been experimentally shown that PDGF plays an important role in the 
migration of smooth muscle cells to the intimal surface (14). 
The place where the graft is sutured to the blood vessels (artery or vein) is called  
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Figure 1-2: Anatomy of vessel walls  
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the anastomosis (Figure 1-1). Native arteriovenous (AV) fistulas and synthetic grafts used 
for hemodialysis commonly develop stenosis and occlusions at the site of anastomosis. 
Histological examinations of graft segments taken from patients have revealed extensive 
hyperplasia at the anastomosis (15, 16). Intimal hyperplasia is a consequence of the 
healing response of the normal vascular wall to injury and is caused by migration and 
proliferation of vascular smooth muscle cells from the media to the intima (8). 
1.3 Drug delivery systems and their mechanisms 
The design of a drug delivery system is an important factor to target the delivery of 
a chemotherapeutic agent to the site of action. Controlled drug delivery systems have 
advantages such as maintaining the drug levels at desired concentration range, requiring 
fewer administrations, and increased patient compliance (17). The important factor in 
controlled drug delivery systems is to achieve a desired drug level in the target tissue for 
as long a duration of time as possible. In the case of conventional tablets or injections, the 
drug level in the blood rises after each administration and decreases until the next dose is 
administered as shown in the Figure 1-3. This type of dosing could produce toxicity at the 
peak concentration and too low a drug level at the trough intervals that it is not effective.  
A controlled delivery systems offers a potential advantage of maintaining the drug level 
constant between the desired maximum and minimum value for a longer period of time 
depending on the application and type of formulation (17). 
Recent developments in the drug dosage forms have been aimed at delivering the 
active molecules to the site of action in the organisms with the help of carriers that also 
protect active molecules from biological degradation. These systems can deliver a 
sustained, slow release of active molecules for longer duration of time (18). Novel  












































Figure 1-3: Diagram showing the advantage of drug delivery systems (b) versus 
conventional tablet or solution (a) in maintaining a desired drug level. 
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therapies for prevention of hyperplasia and vascular stenosis include drug eluting stents, 
perivascular delivery of therapeutic agents, and coated grafts (19). 
To achieve desirable concentrations within the target tissue following the 
administration of a drug in a polymeric system (controlled drug delivery system), it is 
very important to understand the mechanism of degradation of the polymer and the 
process of drug release from the polymer. Different factors play an important role in 
biodegradation of polymers such as chemical structure, composition, presence of ionic 
groups, molecular weight, distribution, sterilization process, physiochemical factors (ion 
exchange, ionic strength, pH), mechanism of hydrolysis (enzymatic or water), site of 
implantation, annealing, and storage history (17). 
Drug release from a polymer system can involve diffusion, degradation or 
swelling followed by diffusion (Figure 1-4).  Diffusion occurs either on a macroscopic 
scale, i.e., through pores of polymer matrix or at molecular level that involves passing 
between polymer chains.  In matrix systems, the polymer and active agent are combined 
to form a homogenous system. Diffusion takes place as the drug passes from the polymer 
matrix to the external environment. The rate of diffusion generally decreases with time in 
such process and requires longer time for the drug to fully release. In case of reservoir 
systems a therapeutic agent is in a polymeric matrix that is surrounded by film or a 
membrane, which is the only factor that limits the release of drug from the polymer. In 
such systems the delivery rate remains constant through out the release. In diffusion 
controlled systems the combination of bioactive agents and polymeric matrices help in 
diffusion of drug through the macromolecular polymeric structure of pores without 
causing any change in the polymer such as degradation or swelling (17). 





Figure 1-4: Release mechanism of drug from bio-degradable polymer: a) bulk- 
eroding systems b) surface eroding systems 
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  In case of environmentally responsive polymers known as intelligent hydrogels, 
environmentally sensitive materials are used which are dry in general and swell when 
they come into contact with body fluids and water. The swelling increases polymer mesh 
size and aqueous content and helps the drug to diffuse from inside to the outer 
environment. At equilibrium, hydrogels absorb 60-90% of fluid and contain only 10-30% 
of polymer. These are called swelling- controlled release systems and are incapable of 
releasing the drug or therapeutic agent until they come in contact of appropriate 
biological environment. Swelling is initiated by changes in the biological environment 
such as pH, temperature and ionic strength. This change is generally reversible. In such 
systems the polymer generally swells when it comes in contact with high pH and 
collapses when it comes in contact with low pH. These systems can be suitable for oral 
drug delivery where the drug needs to be released in the upper small intestine at high pH 
value and requires to be protected from the biological environment with lower pH (17). 
   The above mentioned mechanisms are applicable to polymers that do not undergo 
much change in their chemical structure beyond swelling. Polymers such as polylactide 
(PLA), polyglycolide (PGA), poly(lactide-co-glycolides) (PLGA), polyanhydride and 
polyorthoesters belong to a class of biodegradable polymers that degrade into 
biologically inactive compounds by hydrolysis of polymer chains (17).  
In some cases, polymers are broken down into lactic acid and glycolic acid and 
are finally converted into carbon dioxide and water by entering into metabolic pathways 
to be excreted from the body. The degradation of polymers occurs by two different 
mechanisms: bulk-eroding and surface-eroding.  In bulk-eroding the degradation occurs 
uniformly through out the polymeric matrix by bulk-hydrolysis. In surface-eroding 
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polymers such as polyanhydride and polyothoesters, the degradation takes place only at 
the surface of polymer and the rate of degradation is proportional to the surface area of 
drug delivery system (17). 
1.4 Vascular drug delivery 
Sustained local delivery of drugs helps in reducing the need for multiple dosing and 
thereby helping in reducing toxic effects caused by high systemic exposure of drugs. 
Sustained delivery of drugs is desired for chemically unstable and rapidly degrading 
drugs. Sustained local delivery is achieved by incorporation of a drug into a polymeric 
matrix. This could be achieved at the adventitial aspect of an injured artery or by 
delivering the drug intraluminally, i.e., inside the artery (20). Intraluminal drug delivery 
consists of a stent-graft device. Drug is distributed in the intima and is effective in the 
treatment of thrombosis. Delivery of drug into the intima occurs through diffusion and 
the approach is invasive and can only be performed after surgery. In this type of drug 
delivery system biodegradability and biocompatibility are important issues.  
One major disadvantage of drug eluting stents are increased risk for bleeding if 
drugs like aspirin and clopidogrel are needed after placement of stents (19). Another 
disadvantage of drug eluting stents is that leaching of drug from drug eluting stents could 
be very intensive due to continuous flow of blood through arterial segment, and this may 
require additional drug monitoring with the help of special devices (20). Despite these 
limitations, this approach has shown promising results. In a rabbit model of neointimal 
hyperplasia, heparin delivered locally near the anastomosis of polytetrafluoroethylene 
(PTFE) grafts and veins had an effect on decreasing neo-intimal hyperplasia (21). PTFE 
grafts coated with heparin helped in reducing formation of intimal hyperplasia at 
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anastomosis (22). Local delivery of drugs were effective in the prevention of intimal 
hyperplasia and also helped in reducing systemic toxicities of certain therapeutic agents 
(23). 
Recently there has been an interest in the use of perivascular drug delivery systems 
to inhibit vascular stenosis or restenosis (19). The major advantage of perivascular drug 
delivery includes the application of drug directly to the adventitia surface, which helps in 
blocking adventitial activation and migration of fibroblasts. This also helps create a 
gradient with the highest level of drug concentrations in the adventitial layer and lowest 
level of drug concentrations in endothelial layer (19). Drug delivery takes place by 
diffusion along a concentration gradient. The drug passively diffuses through the vessel 
wall. The vasa vasorum system in the adventitia consists of a network of arterioles, 
venules and capillaries that helps in nourishing the vessel wall components. When the 
drug comes in contact with vasa vasorum the diffusion of the drug is further facilitated 
and the drug is evenly distributed into the inner most arterial segments such as media and 
intima (17).  
1.5 Thermosensitive copolymers 
Thermosensitive polymers show physicochemical response to temperature due to 
their hydrophobic-hydrophilic interactions (24). Because of these physicochemical 
properties, use of thermosensitive copolymers is being explored in various medical 
applications. One major potential for these polymers has been demonstrated in a 
preclinical dog and porcine models by perivascular application around the vascular 
access for inhibition of neointimal hyperplasia (25, 26). The thermosensitive co-polymer 
used in these studies was ReGel™ (BTG plc, West Valley, UT) which is a triblock co-
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polymer consisting of poly-(lactide-co-glycolide) (PLGA)and poly(ethylene glycol) 
(PEG). It has a polydispersity of 1.3 and average molecular weight of ~ 4200 Daltons 
(27).  Aqueous solution of ReGel™ polymer exists as a free-flowing solution at or below 
room temperature thus allowing easy mixing of drug with polymer and creating an easy 
system to inject. It spontaneously turns in to an insoluble gel depot upon raising the 
temperature to body temperature that releases the drug over a period of time. Drug is 
released initially by diffusion and at later stages by combination of polymer degradation 
and diffusion. ReGel™ is totally water-based (no organic solvents used) and can be 
sterilized by terminal filtration or γ–irradiation. In addition to its thermosensitive 
properties, the following advantages of ReGel™ make it more applicable for perivascular 
delivery of anti proliferative drugs (27). 
1) ReGel™ is biodegradable and its degradation products are polyethylene glycol, 
lactic acid and glycolic acid that are generally regarded as safe. 
2) Biodegradation of ReGel™ eliminates the need of depot retrieval after the drug 
has been delivered; hence, it is suitable for repeat injections. 
3) ReGel™ has domains that could dissolve both hydrophilic and hydrophobic drugs 
and most commonly used antiproliferative drugs are hydrophobic. 
4) ReGel™ has an advantage of remaining at the site of injection up to one month. 
As neointimal hyperplasia develops over the time, this property of ReGel™ 
makes it applicable for perivascular delivery of anti proliferative drugs. 
5) The rate of drug release from ReGel™ could be controlled by changing the lactide 
to glycolide ratio in the polymer composition.  
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The aim of these studies was to investigate the release profiles of a potential 
antiproliferative drug from ReGel™ so that it can be used for inhibiting vascular smooth 
muscle cells in future studies using an animal model of neointimal hyperplasia. 
1.6 Antiproliferative drugs  
Various studies have tried the use of chemotherapeutic agents for prevention of 
neo-intimal hyperplasia including heparin (28), tranilast (29), perindopril (an angiotensin-
converting enzyme inhibitor) (30) and calcium channel blockers like verapamil and 
diltiazem (31).  These have shown limited success.  
  Rapamycin is a Food and Drug Administration (FDA) approved immuno 
suppressive agent used to prevent rejection after organ transplantation. It acts by 
specifically binding to immunophilins (32). Gregory et al. have shown its dose dependent 
inhibition of arterial intimal thickening in a rat model (33, 34). Later studies 
demonstrated its effect on inhibiting proliferation of vascular smooth muscle cells in vitro 
(35). It has recently been shown that rapamycin significantly reduces restenosis in 
porcine coronary models (36). Dipyridamole is a weak base (37) and an antiproliferative 
drug which acts by inhibiting phosphodiesterases and thereby increasing intracellular 
cyclic nucleotide levels (38). Various studies have shown its efficacy in inhibiting PDGF 
and bFGF- induced vascular smooth muscle cell proliferation (39, 40). The mechanism of 
action of dipyridamole is related to inhibiting cyclic nucleotide phosphodiesterases that 
lead to increase in the cAMP and cGMP levels (41, 42). Paclitaxel is a chemotherapeutic 
agent that is effective at inhibiting various cancer cell lines and tumors. Intravenous 
administration with Cremophor EL has been unsuccessful due to the allergic reactions. 
However, it could be used for local administration in the prevention of neo- intimal 
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hyperplasia. Recent studies have shown that paclitaxel could inhibit neo-intimal 
hyperplasia in arteriovenous hemodialysis grafts (25, 43).   
Most of the above mentioned drugs have been shown to inhibit VSMC proliferation 
in different in vitro test conditions but these have not been successful in vivo. Therefore, 
our group is investigating and exploring the potential application of imatinib mesylate for 
inhibiting neo-intimal hyperplasia both in vitro and in vivo. 
1.7 Imatinib mesylate  
Imatinib mesylate is a synthetic, 2-phenylamino-pyrimidine derivative chemically 
recognized as 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[4-(3-pyridinyl)-2-
pyrimidinyl]amino]-phenyl] benzamide methanesulfonate (Figure 1-5) (44). Its 
commercial trade name is Gleevec™ (Novartis Pharmaceuticals, Basel, Switzerland) (44). 
It is a potent tyrosine kinase inhibitor approved for the treatment of gastrointestinal 
tumors and chronic myelogenous leukemia (44).  Imatinib mesylate has a low molecular 
weight (589.7 Da) and shows good aqueous solubility at low pH (<5.5) but is poorly 
soluble or insoluble at neutral and alkaline pH. In nonaqueous solvents, the drug 
substance is freely soluble to very slightly soluble in DMSO, methanol, and ethanol but is 
insoluble in n-octanol, acetone, and acetonitrile (45). It has also been found that standard 
doses of imatinib can be safely administered to patients on hemodialysis with renal 
failure at any stage (46). Pharmacokinetic studies of imatinib show that it has excellent 
bioavailability following oral administration in humans and is mainly metabolized by 
cytochrome P450 3A4 (47). The currently available oral formulation has other inactive 
ingredients like crospovidone, colloidal silicon dioxide, hydroxypropyl methyl cellulose, 
microcrystalline cellulose, and magnesium stearate (44). It is supplied as 100 mg of 
















Figure 1-5: Chemical structure of imatinib mesylate. 
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imatinib mesylate equivalent. Li et al. (48), have recently showed the potential 
application of imatinib mesylate in inhibiting venous smooth muscle cell (VSMC) 
proliferation. This evidence suggested that imatinib acts on the PDGF receptor (PDGFR) 
tyrosine kinase inhibitor that leads to the inhibition of the vascular smooth muscle cells 
proliferation. The concentrations of imatinib mesylate salt required to inhibit 50% of the 
proliferative vascular smooth muscle cells (IC50) in human smooth cells was found to be 
0.5μM (48). Therefore, this study was aimed at exploring whether it was feasible to 
incorporate imatinib in a local delivery system using a thermosensitive copolymer in 
order to inhibit proliferative smooth muscle cells in the context of AV fistula anastomotic 
hyperplasia. 
1.8 Significance of this work 
Before further application of imatinib mesylate for prevention of hemodialysis 
vascular access stenosis, we need to characterize the release profile of the drug from the 
delivery system and explore factors that impact this release. The duration of drug release 
from the polymer is an important factor to achieve therapeutic concentrations at the target 
tissue and defines the frequency of administration of the drug/ polymer system for the 
complete prevention of intimal hyperplasia. This study focuses on the release profiles of 
imatinib release from ReGel™ using several in vitro release experiments. Inhibitory 
concentrations of imatinib needed to prevent vascular smooth muscle cell proliferation 
(IC50) are evaluated using these in vitro cell culture experiments. Characterization of the 
imatinib/ReGel™ system to attain desired release profiles in the target tissue have also 
been proposed and discussed. 
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  The main objectives of this study are: 
1) To determine the effect of the free base of the drug on the proliferation of 
vascular smooth muscles cells and compare the IC50 values from the literature. 
2) To determine the duration of drug release from a thermosensitive co-polymer 
under in vitro conditions. 
3) To assess imatinib/ReGel™ system for the sustained release of the drug from the 
thermosensitive polymer in preventing vascular access stenosis. 
 




RELEASE PROFILE OF IMATINIB MESYLATE  
FROM REGEL™
Introduction 
In a solid dosage form there are two main ingredients. One is the active substance 
or the drug that elicits a pharmacological response and the others are the inactive 
substances and often known as excipients that do no have any effect on the 
pharmacological response (49). Imatinib mesylate is commercially available in two solid 
dosage forms: tablet or capsule (44, 48). Gleevec™ film – coated tablets consist of 100 
mg of imatinib mesylate along with other inactive ingredients such as colloidal silicon 
dioxide (NF), crospovidone (NF), hydroxypropyl methyl cellulose (USP), magnesium 
stearate (NF) and microcrystalline cellulose (NF). Tablet coating is made up of ferric 
oxide, red (NF); ferric oxide, yellow (NF); hydroxyl propyl methylcellulose (USP); 
polyethylene glycol (NF) and talc (USP) (44). Gleevec capsules consists of 100 mg 
equivalent of imatinib mesylate along with other inactive ingredients like colloidal silicon 
dioxide (NF), crospovidone (NF), magnesium stearate (NF) and microcrystalline 
cellulose (NF) (50). Li et al. (48), have recently showed the potential application of 
imatinib mesylate in inhibiting venous smooth muscle cell (VSMC) proliferation which is 
responsible for the formation of neointimal hyperplasia.  
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In order for a drug to inhibit neointimal hyperplasia around the hemodialysis 
vascular access it is also important to look at the rate at which the drug is getting released 
from the drug delivery system like ReGel™. An ideal drug delivery system that would be 
suitable for inhibiting hyperplasia should not have too quick release rates of the drug as 
this could interfere with the healing process. On the other hand a prolonged rate may not 
provide adequate concentrations in the tissue for inhibiting stenosis. Imatinib mesylate 
was not commercially available in purest form as only active ingredient, but available in 
marketed forms of tables and capsules with active ingredient and other excipients as 
mentioned above. Since these excipients could affect the release rates of imatinib 
mesylate from ReGel™, it was essential to study the release rates of both tablet and 
capsule.  The one with a prolonged and sustained release profiles would be more 
desirable for further investigation in preventing neointimal hyperplasia. 
2.2 Methods 
2.2.1 Materials. Imatinib mesylate manufactured by Novartis Pharmaceuticals 
(Basel, Switzerland) was obtained from the Veterans Affairs Medical Center Pharmacy as 
100 mg tablets and 100 mg capsules. ReGel™ was obtained from BTG Inc. (West Valley, 
UT). All other chemicals were purchased from Sigma Aldrich Ltd (ST. Louis, MO). 
2.2.2 Standard curve of imatinib mesylate. Tablets were ground into powder 
with the help of mortar and pestle. Standard solutions were prepared in the concentration 
range from 2.5 to 60 ug/mL in 5% ethanol in phosphate buffered saline (PBS, pH 7.4). 
The standard solutions were measured by absorbance at 265nm using UV-
spectrophotometry by subtracting the absorbance of 5% ethanol in phosphate buffered 
saline (PBS, pH 7.4). 
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2.2.2 Release kinetics of imatinib mesylate tablet. Two mg of imatinib 
mesylate (actual amount of drug in the powder) were suspended in 2 mL of ReGel™ 
under cold conditions (4 oC) in a scintillation vial.  The drug-ReGel™ mix was allowed to 
solidify at 25 oC. Following the solidification of the drug-ReGel™ mix, 15 mL of release 
medium consisting of 5% ethanol in phosphate buffered saline (PBS, pH 7.4) was added 
into the vial. The vial was then placed in the Gyratory water bath shaker (G76D, New 
Brunswick Scientific Co Inc, NJ) and agitated at 50 rpm while the temperature was 
maintained at 37oC and covered to protect from light. Release profiles in two procedures 
were determined in sink and nonsink conditions. For sink conditions, 50μL of the release 
medium were taken from the scintillation vial at specific time points for further analysis 
of imatinib mesylate using a UV-spectrophotometer. The rest of the release medium was 
discarded in the scintillation vial and replaced by fresh release medium at each sampling 
time point. In case of nonsink conditions, 50μL of the release medium were taken from 
the scintillation vial at specific time points for further analysis of imatinib mesylate using 
the UV-spectrophotometer method but only 50uL of fresh release medium was replaced 
in the scintillation vial. 
2.2.3 Release kinetics of imatinib mesylate capsule. The imatinib mesylate 
powder was removed from the capsule and 2 mg (actual amount of drug in the powder) 
was suspended in 2 mL of ReGel™ under cold conditions (4 oC) in a scintillation vial.  
The rest of the procedure was similar to that of the imatinib mesylate tablet. The release 
kinetics were obtained for both sink and nonsink conditions. 
2.2.4 Data analysis. All in vitro experiments were performed with n=5 and 
each of the release rate profiles (% cumulative release versus days) obtained from in vitro 
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experiments were fitted to a monoexponential equation (Equation 1) using Sigmaplot 
(San Jose, CA). 
%Cumulative release =100*(1-exp-kt)    Equation 1 
where k is the rate constant (day-1) and t is the time in days. The rate constants of each 
experiment were expressed as the mean and standard deviation (SD). Release rates of 
sink and nonsink conditions and release rates of capsule versus tablets were compared 
using analysis of variance (ANOVA) with correction for multiple comparisons, where p 
<0.05 was considered to be statistically significant. Number of days to reach 100% 
release was calculated from the inverse of mean rate constants of each profile. 
2.2.5 Paclitaxel and dipyridamole release from ReGel™. The release data of 
dipyridamole from ReGel™ were obtained from Figure 4 of the study of Zhu et al. (39). 
The results in this study showed that it takes approximately 18 days for dipyridamole to 
be 100% released  from ReGel™ (39). Similarly paclitaxel release from ReGel™ was 
obtained from figure 5 of Zentner et al’s study which showed that it takes approximately 
45 days for paclitaxel to be 100% released from ReGel™. This information was used to 
the plot the relationship between log P of drugs and the time of 100% drug release (27). 
2.3 Results 
A linear standard curve was obtained for imatinib mesylate concentrations and 
absorbance with an r2 value of 0.99, with a slope of 0.0515 (Figure 2-1).  The standard 
curve of imatinib mesylate was reproducible for either capsule or tablet. The release rates 
of imatinib mesylate in sink and nonsink conditions obtained from tablet or capsule are 
shown in Table 2.1. There was no statistically significant differences in release rates 






























Figure 2-1: Standard curve of imatinib mesylate in 5% ethanol in phosphate 
buffered saline (PBS, pH 7.4) (n=5). 
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Table 2.1: Release rates of imatinib mesylate from tablet or capsule in sink and 
nonsink conditions. Comparison by ANOVA with correction for multiple 




Experiment Release rate (per day) Number of days for 
100% release 
 Mean S.D.  
Nonsink tablet 0.3224 0.0762 3 
Nonsink capsule 0.216 0.0916 4 
Sink Tablet 0.3191 0.0623 3 
Sink Capsule 0.2816 0.0724 4 
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between sink and nonsink conditions for imatinib mesylate obtained from tablet (p>0.05) 
(Table 2.1, Figure 2-2). There were no significant differences in release rates between 
sink and nonsink conditions for imatinib mesylate obtained from capsule (Table 2.1, 
Figure 2-3). Within 3-4 days approximately 100% of the imatinib mesylate obtained from 
either capsule or tablet was released in both sink and nonsink conditions (Figure 2-4). 
When log P (octanol-water partition coefficient) values are taken into consideration there 
is a correlation between the log P value of the drug and its release from ReGel™   (Figure 
2-5) (47, 51, 52). With a decrease in the log P value there is a faster release of the drug 
from ReGel™. Figure 2-5 illustrates the relation between the log P of drug value and the 
duration of the drug release from the thermosensitive polymer ReGel™. 
2.4 Discussion 
           In  this study,  we  found  that the  drug release  from imatinib  mesylate occurs  
within  a  week.  The results  also showed  that  the sink  and nonsink  conditions did  not  
influence the  release of the drug from the  ReGel™.  This shows that  even after in vivo  
administration where conditions are likely to be nonsink the release of imatinib is likely to  
be rapid.  The results showed  that there  was no significant  difference in  release profiles  
between  results either obtained from capsule or tablet. Since, imatinib tablets were  sub-
jected to grinding  using mortar and pestle, there is a possibility of differences in the  
particle size and particle size distribution of tablets. Therefore, in order to decrease this
variability  that could affect  the release profiles,  imatinib obtained from the capsule is  
preferable over tablet for further in vivo studies. 
The results show a correlation between log P value of the drug and duration of the 
drug release. With the decrease in the log P value and increase in the hydrophilicity, there  











































Fitted equation (average rate) sink tablet
Fitted equation (average rate) nonsink tablet
Sink tablet concentration-time plot
Nonsink tablet concentration- time plot
 
Figure 2-2: Release profiles of imatinib mesylate obtained from tablet in sink and 
nonsink conditions. The release rates between sink and nonsink conditions           
were not statistically significant. 















































Fitted equation (average rate) sink capsule
Fitted equation (average rate) nonsink capsule
Sink capsule concentration-time plot




Figure 2-3: Release profiles of imatinib mesylate obtained from capsule in sink and 
nonsink conditions. The release rates between sink and nonsink conditions were   


















































Fitted equation (average rate) sink tablet
Fitted equation (average rate) nonsink tablet
Fitted equation (average rate) sink capsule
Fitted equation (average rate) nonsink capsule
Sink tablet concentration-time plot
Nonsink tablet concentration- time plot
Sink capsule concentration-time plot
Nonsink capsule concentration- time plot
 
 
Figure 2-4: Release profiles of imatinib mesylate obtained from capsule and tablet in 
sink and nonsink conditions. The release rates between sink and nonsink conditions 
were not statistically significant. 
 
 































Days for 100% release =12.54*log P-22.9 (r2=0.88)
 
 
Figure 2-5: Relation between log P and duration of drug release from ReGel™ 
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was a faster release of the drug from ReGel™. The possible mechanism behind the 
different release rates of the drug could be due to their partitioning in the hydrophilic 
domain and the hydrophobic domain of the ReGel™. In case of imatinib mesylate that has 
a log P value of 1.99 the drug was concentrated in the hydrophilic domain of ReGel™ and 
was released by diffusion from the hydrophilic domain of ReGel™. This result in 
monophasic release profiles of imatinib mesylate from the ReGel™ (Figure 2-2, 2-3 and 
2-4). The most probable mechanism of imatinib release from the polymer occurs by 
diffusion and some matrix degradation. In the case of dipyridamole, which has a log P 
value of 3.9, the drug partitions between both the hydrophilic and hydrophobic domains 
of ReGel™ and results in a two stage release pattern (39). The first stage of the release 
profile is due to the burst effect from the hydrophilic domain and the later stage is the 
release from the hydrophobic domain (39). On the other hand, in case of highly 
hydrophobic drugs like paclitaxel, the drug is mainly in the hydrophobic domain, leading 
to the sustained release of drug from the hydrophobic core of ReGel™ over time (27). 
 In order to inhibit neointimal hyperplasia, these results suggest that imatinib 
ReGel™ mixture would need to be replenished once every week. Although the drug-
ReGel™ mixture can be administered even after surgery, this administration would likely 
be too frequent compared to other antiproliferative drugs. The fast release rates of the 
drug could hinder the healing process at the anastomosis which occurs during the first 
week. An ideal system should have an optimal release rate such that release profiles are 
greater than 3-4 days, ideally lasting for months without need for readministration.  




EXTRACTION OF FREE BASE OF IMATINIB MESYLATE  
AND ITS RELEASE KINETICS FROM REGEL™ 
Introduction  
Imatinib mesylate is chemically known as 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-
methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-phenyl]- benzamide  methane sulfonate. 
The molecular formula is C29 H31 N7O.CH4SO3 and molecular weight is 589.7 with a pKa 
ranging from 3-8 (44). It is soluble in aqueous buffers of pH less than or equal to 5.5. The 
piperazinylmethyl group of the molecule provides the water solubility and oral 
bioavailability (53). Based on pH-dependent capillary zone electrophoresis, it was 
claimed that protonation of neutral imatinib starts below pH 5 (54, 55). Studies showed 
that imatinib is predominantly neutral, monocationic and tricationic at intestinal, blood 
and gastric pH, respectively (55). Therefore, this suggests that imatinib will be in a 
monocationic phase at neutral pH 7.4. Knowing the pKa value of imatinib and its 
protonation state at various pH values, the salt form can be converted to its free base. 
This free base of imatinib is expected to be more lipophilic than its salt form. Higher 
lipophilicity of free base over its salt form could potentially help prolong the release of 
imatinib from ReGel™. We were therefore, interested in extracting a free base of the salt 
form of imatinib to investigate its release rate from ReGel™. 
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3.2 Methods 
3.2.1 Materials. Imatinib mesylate manufactured by Novartis Pharmaceuticals 
(Basel, Switzerland) was obtained from the Veterans Affairs Medical Center Pharmacy as 
100 mg of imatinib mesylate along with other excipients. ReGel™ was obtained from 
BTG Inc. (West Valley, UT). All other chemicals were purchased from Sigma Aldrich 
Ltd (St. Louis, MO). 
3.2.2 Extraction of free base. Imatinib mesylate tablets were ground to a fine 
powder with the help of mortar and pestle. The powder was added to water whose pH 
was changed to 3.14 by 1N HCl followed by continuous stirring for 5 minutes in order to 
solubilize imatinib mesylate. After the dissolution, the solution was filtered to remove 
undissolved excipients.  This mixture was further treated by changing to pH 12 by adding 
1N NaOH.  This resulted in the precipitation of the free base of imatinib. The solution 
was further centrifuged using an ultracentrifuge (Allegra 6R centrifuge, Beckman Coulter 
Inc.) and the supernatant was discarded. The remaining precipitate was lyophilized using 
a lyophilizer (Freezone 6 freeze dry system, Labconco Corp).  The presence of free base 
of imatinib was confirmed with the help of reverse phase high performance liquid 
chromatography (RP-HPLC) method (Agilent Technologies, CA) using a C-8 column 
(Waters, MA) (250 mm x 4.6 mm id; particle size 5 μm) with UV-Detection (Agilent 
Technologies, CA). The samples were eluted in a mobile phase of 0.02M potassium 
dihydrogen phosphate – acetonitrile (7:3,v/v) at a flow rate of 1ml/min. The mobile phase 
was filtered through a 0.22μm filter (Millipore, MA) and was degassed under vacuum 
prior to use. The detector was set at a wavelength of 265 nm. Both the free base and the 
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salt form (mesylate) of imatinib samples were analyzed using the above mentioned 
chromatographic conditions. 
3.2.3 Standard curve of free base of imatinib. The lyophilized powder of free 
base of imatinib obtained by this separation was used to prepare standard solutions in the 
concentration range from 0.6 to 30 ug/mL in 5% ethanol in phosphate buffered saline 
(PBS, pH 7.4) with 1% (v/v) Cremophor EL and 1% (v/v) Tween 80. The standard 
solutions of free base of imatinib were measured by absorbance at 265nm using a UV-
spectrophotometer method by subtracting the absorbance of 5% ethanol in phosphate 
buffered saline (PBS, pH 7.4) with 1% (v/v) Cremophor EL and 1% (v/v) Tween 80. 
3.2.4 Release kinetics of free base of imatinib. Two mg equivalents of 
extracted free base of imatinib was suspended in 2 mL of ReGel™ under cold conditions 
(4 oC) in a scintillation vial.  The drug-ReGel™ mix was allowed to solidify at 25 oC. 
Following the solidification of the drug-ReGel™ mix, 15 mL of release medium 
consisting of 5% ethanol in phosphate buffered saline (PBS, pH 7.4) with 1% (v/v) 
Cremophor EL and 1% (v/v) Tween 80 was added into the vial. The vial was then placed 
in the Gyratory water bath shaker (G76D, New Brunswick Scientific Co Inc, NJ) and 
agitated at 50 rpm with the temperature maintained at 37oC and covered to protect from 
the light. Release profiles in two procedures were followed that created sink and nonsink 
conditions. For sink conditions, 50μL of the release medium were taken from the 
scintillation vial at specific time points for further analysis of free base of imatinib using 
a UV-spectrophotometer method. The rest of the release medium was discarded in the 
scintillation vial and replaced by fresh release medium at each sampling time points. In 
case of nonsink conditions, 50μL of the release medium were taken from the scintillation 
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vial at specific time points for further analysis of free base of imatinib using the UV-
spectrophotometer method but only 50uL of fresh release medium was replaced in the 
scintillation vial. 
3.2.5 Data analysis. All in vitro experiments were performed with n=5 and each 
of the release rate profiles (% cumulative release versus days) obtained from in vitro 
experiments were fitted to a monoexponential equation using SigmaPlot (San Jose, CA). 
The rate constants of each experiment were expressed as the mean and standard deviation 
(SD). Release rates of sink and nonsink conditions and release rates of free base versus its 
mesylate form (tablet) were compared using one way analysis of variance (ANOVA), 
where p <0.05 was considered to be statistically significant. Number of days for 100% 
release was calculated from the inverse of mean rate constants of each profile. 
3.3 Results 
Under the chromatographic conditions the free base of imatinib and imatinib mesylate 
eluted at a retention time of 14.85 and 13.6 minutes respectively (Figure 3-1). Since the 
separation was performed in RP-HPLC, this suggests that free base is slightly 
hydrophobic to the mesylate salt form because compounds with greater retention times 
will elute slowly because of increase interactions with the hydrophobic column. Linearity 
was obtained for the standard curve of free base of imatinib versus absorbance with an r2 
value of 0.99 and a slope of 0.227 (Figure 3-2). The release rates of free base of imatinib 
under sink and nonsink conditions were similar without any significant difference (Figure 
3-3) with 100% of the drug released within ~2-3 days (Table 3.1). The release rates of 
free base of imatinib was not statistically different than the release rates of imatinib 
mesylate (obtained from the tablet in chapter 2) from the ReGel™ (p>0.05) (Figure 3-4,  
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Figure 3-2: Standard curve of free base of imatinib in 5% ethanol in phosphate 
buffered saline (PBS, pH 7.4) with 1% (v/v) Cremophor EL and 1% (v/v)         
Tween 80 (n=5). 
 












































Nonsink  free base
Fitted equation (average rate) sink free base
Fitted equation (average rate) nonsink free base
Sink free base concentration-time plot








37    
Table 3.1: Release rates of imatinib salt (mesylate) and free base from ReGel™. 
Comparison by ANOVA with correction for multiple comparisons was not 
statistically significant (p>0.05). 
 
 
Experiment Release rate (per day) Number of days for 
100% release 
 Mean S.D.  
Nonsink Free Base 0.5349 0.1424 2 
Nonsink Salt 0.3224 0.0762 3 
Sink Free Base 0.5136 0.117 2 
Sink Salt 0.3191 0.0623 3 
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Fitted equation (average rate) sink tablet
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Sink tablet concentration- time plot
 
 
Figure 3-4: Release profile of free base of imatinib and imatinib mesylate (tablet) 
from ReGel™ under sink conditions. 
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Figure 3-5). 
3.4 Discussion 
The data show that the free base of imatinib eluted at a later time point in the 
reverse phase HPLC suggesting that the base is more hydrophobic than the salt. 
However, the retention times on the RP-HPLC of free base and its salt were fairly similar 
(14.8 vs 13.6 min), suggesting that the free base is only slightly hydrophobic than its salt 
form. Based on these results free base of imatinib would not have affected the release rate 
from ReGel™ significantly compared to its salt form. This was shown by the release 
profiles of the free base of imatinib from ReGel™ compared to the imatinib mesylate salt.  
  In order for imatinib concentration to maintain inhibition of neointimal 
hyperplasia, the results suggest that imatinib free base ReGel™ mixture would need to be 
replenished every 3 days. Thus neither imatinib free base nor its salt can be used 
successfully in this system because the release of imatinib is too quick (less than a week). 
This modified ReGel™ or microsphere/ReGel™ delivery systems could potentially extend 
the release of free base from ReGel™ which would help in inhibiting hemodialysis 
vascular access stenosis. 
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Figure 3-5: Release profile of free base of imatinib and imatinib mesylate (tablet) 












EFFECT OF IMATINIB ON SMOOTH MUSCLE CELLS 
Introduction 
Naturally occurring proteins like growth factors are responsible for stimulating 
cellular proliferation and cellular differentiation (56). One growth factor, platelet-derived 
growth factor (PDGF) is dimeric glycoprotein composed of two A (-AA) or two B (-BB) 
chains or a combination of the two (-AB). PDGF-AB released from activated platelets, 
SMC and monocytes has been found to be an important mediator of SMC proliferation 
(56). The major functions of PDGF includes embryonic development, cell proliferation, 
cell migration, and angiogenesis (56). It has been shown that PDGF released from 
activated platelets, smooth muscle cells (SMC) and monocytes are important factors for 
SMC proliferation (57, 58). PDGF activates cellular response through a cell surface 
receptor known as the PDGF receptor (PDGFR). In vivo studies in various animal models 
have shown that inhibiting PDGFR causes antiproliferative effects (59, 60).  
Imatinib mesylate (Gleevec) has been shown to be an effective tyrosine kinase 
inhibitor used in the treatment of chronic myelogenous leukemia and has specificity 
towards c-Abi, c-kit and PDGFR (44). Antiproliferative effects of imatinib have been 
demonstrated using in vivo restenosis models (61). A recent study by Li et al.  has shown 
the efficacy of imatinib mesylate salt on the PDGF-AB induced proliferation of human 
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arterial and venous smooth muscle cells (48). In this study, we investigated the 
antiproliferative effects of free base of imatinib on vascular smooth muscle cells using 
the  Brdu( 5-Bromo, 2- deoxy uridine) assay which measures the DNA synthesis of 
proliferating cells (48).  
4.2 Methods 
4.2.1 Materials. All cell culture reagents were purchased from Cascade 
Biologics (Portland, OR), except fetal bovine serum (FBS), which was from Atlanta 
Biologics (Lawrenceville, GA). Recombinant PDGF-AB was purchased from R&D 
Systems (Minneapolis, MN). Imatinib mesylate manufactured by Novartis 
Pharmaceuticals (Basel, Switzerland) was obtained from Veterans Affairs Medical Center 
Pharmacy as 100 mg of imatinib mesylate tablet.  Imatinib free base was obtained using 
the procedure described in Chapter 3.  All other chemicals were purchased from Sigma 
Aldrich Ltd (St.Louis, MO). The DNA synthesis of SMC in culture was assessed using 
the 5-bromo-2’deoxyuridine (BrdU) incorporation Cell proliferation Biotrak ELISA kit 
purchased from Amersham Biosciences (Piscataway, NJ). 
4.2.2 Cell culture. Porcine venous smooth muscle cells (SMC) were isolated 
from femoral veins of Yorkshire cross domestic pigs by collagenase and elastase 
digestion. Cells were grown to 70-80% confluence and then rendered quiescent by 
incubation with medium containing 0.5% FBS without any additional growth factors. All 
cells were in culture medium at a temperature of 370C and humidified in 5% CO2 
incubator. Cells from passages 3 to 7 were used for the following experiments.  
4.2.3 Cell proliferation assay. Venous smooth muscle cells were seeded in 
culture medium at a density of 1x104 cells/well on 96 well plates for 48 hours and then 
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were treated with various concentrations of imatinib free base in dimethyl sulfoxide (0 
(control), 0.05, 0.5, 5μM) for 90 minutes followed by stimulation with 50 ng/mL of 
PDGF-AB for the cells to proliferate. After this, BrdU labeling solution was added at a 
concentration of 10μM and incubated for 12 hours. The culture medium was then 
removed, the cells fixed and the DNA was denatured with the help of a fixative, which 
was removed after 30 minutes incubation. A peroxidase labeled anti BrdU monoclonal 
antibody Amersham Biosciences (Piscataway, NJ) was then added and the plate was 
incubated for 90 min at room temperature. A Microplate reader ( Multiskan Ascent, 
Thermoelectron corp, San Jose, CA) was used to detect the BrdU-antibody complexes 
using colorimetric reaction  at an optical density of 450 nM and the dynamic linear range 
was found to be up to 200 ng/mL of  PDGF-AB (48).  
4.2.4 Statistical analysis. The results are reported as mean ± SD and the 
comparison between drug-treated and control groups were performed using the two tailed 
student’s t-test performed in Excel (Microsoft, Seattle, WA). Statistically significant 
results are defined as p < 0.05. 
4.3 Results 
The results (mean ± SD) show that in the presence of free base of imatinib there 
was inhibition of proliferation of porcine venous smooth muscle cells compared to 
control (Figure 4-1). At 0.05 µM of the free base of imatinib only 69.6±8.4 % of the cells 
proliferated compared to 100% of the control. At 0.5 μM of the free base of imatinib only 
70.1±8.4 % of the cells proliferated compared to 100% of the control. At 5 µM of the free  
base of imatinib only 48.2±13 % of the cells proliferated compared to 100% of the 



























Figure 4-1: Cell proliferation assay of venous smooth muscle cells using imatinib 
free base (FB) of imatinib stimulated with 50 ng/mL of PDGF-AB. Results  
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control. An exact IC50 could not be determined because the dose response relationship 
could not be established due to the limited number of concentrations used in this study. 
To achieve ~50% inhibitory concentrations in cell proliferation the concentrations of 
imatinib free base would likely have to be between 0.5-5 µM (Figure 4-1).  
4.4 Discussion 
A complete dose-response was not available hence an accurate estimate of IC50 values 
of free base could not be established for our study. However, based on the concentrations 
studied, the IC50 is expected to be between 0.5-5 µM and is likely close to 5 µM since 
this stopped the cell proliferation by 50%. The literature reported 50% inhibitory 
concentration value for human vascular smooth muscle cell proliferation was 0.5 µM 
using imatinib mesylate salt (48). One difference in these IC50 values is the difference in 
species, with free base experiments porcine cells were used whereas the studies 
conducted by Li et al. (48) were carried out in human smooth muscle cells.  A complete 
dose response of free base and the human smooth muscle cells would be needed for 
proper comparison of the IC50.  
It has been noted that antiproliferative effects could differ from the toxic effects as in 
the case of dipyridamole were it was found that the concentrations required for toxic 
effects could be 5-10 fold higher than the concentrations required for antiproliferative 
effects (39). The clinical end point whether it is the antiproliferative dose or the dose that 
induces toxicity has to be further evaluated for imatinib salt and its free base in both in 
vitro and the in vivo experiments. These preliminary results will be helpful in designing 
appropriate drug delivery systems for the prevention of hemodialysis vascular access 
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stenosis for imatinib mesylate salt or its free base. With the current ReGel™/imatinib 
delivery system, to achieve these concentrations in vascular tissue either with free base or 
its salt is feasible but the since the release of imatinib would be quick, further 
modifications of release system as mentioned in Chapter 2 would be needed to see a 
sustained effect in the inhibition of proliferation of vascular smooth muscle cells.  
In the presence of PDGF-AB at 50 ng/mL without any imatinib there was 
proliferation of VSMC (48). This concentration of PDGF -AB was in the same range 
used in other PDGF-stimulated cell proliferation studies and in the range of serum 
concentrations of variety of patient populations (48).  However, a reduced concentration 
of PDGF-AB may have less proliferative effect on the VSMCs and as result more 
inhibition by imatinib mesylate. These can be explored in further studies depending on 
the variations in the serum concentration of PDGF-AB in patient populations to 

















    
CHAPTER 5  
SUMMARY 
 
Hemodialysis vascular access dysfunction is a major problem and one of the 
major causes is vascular access stenosis (25, 26). One of the ways to reduce the vascular 
access stenosis is by perivascular delivery using polymeric systems that release 
antiproliferative drugs (25, 26). ReGel™, which is a novel thermosensitive polymer, can 
be used as a polymeric system for perivascular delivery (25, 26). The proper choice of 
antiproliferative drugs with ReGel™, however, needs to be explored and evaluated before 
such a use. In this study we evaluated the use of imatinib mesylate with ReGel™ for 
perivascular delivery using in vitro studies.  
 Imatinib mesylate was commercially available in capsule and tablets (44, 50). The 
in vitro release studies show that 100% of imatinib mesylate would release from imatinib 
mesylate-ReGel™ mixture in 2-4 days both in sink and nonsink conditions. Use of free 
base of imatinib did not prolong the release from ReGel™ beyond 3 days.  Therefore, in 
order to inhibit hyperplasia imatinib must be replenished every 2-4 days in the ReGel™, 
which is not a feasible solution.  Therefore, further investigation to prolong the release 
rate of imatinib from ReGel™ needs to be explored if imatinib is to be used in this 
application. One of the methods to achieve this is by modifying the drug delivery system. 
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For instance, Zhu et al. showed that by incorporating drug in microspheres within 
ReGel™ can prolong the release of the drug substance (62). Other researchers have 
shown that by modifying PEG on polymer matrices they were able to decrease the burst 
effect for paclitaxel in a different delivery system than ReGel™ for perivascular 
applications (63, 64).  Also changing the ratio of lactide to glycolide ratio from 3:1 
(ReGel™) to 4:1 (ReGel-2™) there was a suppression of the burst effect and sustained 
release of insulin (Figure 5-1) (27).  Further work is needed to prolong the release profile 
from ReGel™ and all the above studies can be used for improving the release profile of 
imatinib from ReGel™. 
 The cell culture studies showed that inhibitory concentrations required to inhibit 
50% of vascular smooth muscle cell proliferation in porcine smooth muscle cells is 
between 0.5-5 µM for the free base of imatinib. Further evaluation is needed to determine 
the concentrations required for 50% or 80% of inhibition on vascular smooth muscle 
cells. Additional experiments can be performed on the relationship between PDGF-AB 
levels and the imatinib concentrations that are required for antiproliferative effect. 
 Thus, a system that can sustain > 5 µM locally for up to 2-3 weeks would be 





























Figure 5-1: Release profile of insulin from ReGel™ versus ReGel-2™ with lactide to 
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